Robert Lasser

6.4k total citations · 4 hit papers
94 papers, 4.8k citations indexed

About

Robert Lasser is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, Robert Lasser has authored 94 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Psychiatry and Mental health, 22 papers in Pharmacology and 14 papers in Cognitive Neuroscience. Recurrent topics in Robert Lasser's work include Schizophrenia research and treatment (28 papers), Treatment of Major Depression (19 papers) and Attention Deficit Hyperactivity Disorder (18 papers). Robert Lasser is often cited by papers focused on Schizophrenia research and treatment (28 papers), Treatment of Major Depression (19 papers) and Attention Deficit Hyperactivity Disorder (18 papers). Robert Lasser collaborates with scholars based in United States, Switzerland and United Kingdom. Robert Lasser's co-authors include John M. Kane, Daniel R. Weinberger, Nancy C. Andreasen, William T. Carpenter, Stephen R. Marder, Cynthia A. Bossie, Georges M. Gharabawi, Trey Sunderland, Stephen Kanes and Young Zhu and has published in prestigious journals such as New England Journal of Medicine, American Journal of Psychiatry and Neurology.

In The Last Decade

Robert Lasser

92 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

2005 1.7k citations John M. Kane, Robert Lasser et al. profile →
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

2017 411 citations Susanne Ostrowitzki, Robert Lasser et al. Alzheimer s Research & Therapy profile →
Effect of Zuranolone vs Placebo in Postpartum Depression

2021 149 citations Kristina M. Deligiannidis, Samantha Meltzer‐Brody et al. profile →
Zuranolone for the Treatment of Postpartum Depression

2023 93 citations Kristina M. Deligiannidis, Samantha Meltzer‐Brody et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Lasser United States	33	3.4k	1.1k	1.0k	927	633	94	4.8k
Myrto Samara Germany	25	4.0k 1.2×	733 0.7×	969 1.0×	855 0.9×	763 1.2×	80	5.9k
Antony Loebel United States	41	5.3k 1.6×	829 0.8×	1.1k 1.1×	1.1k 1.2×	639 1.0×	226	6.4k
Larry Alphs United States	36	3.8k 1.1×	937 0.9×	1.1k 1.1×	921 1.0×	584 0.9×	174	5.2k
Bruce J. Kinon United States	47	5.0k 1.5×	789 0.8×	1.1k 1.1×	845 0.9×	882 1.4×	153	7.4k
Brian Sheitman United States	33	4.6k 1.4×	1.2k 1.1×	1.7k 1.6×	535 0.6×	682 1.1×	87	6.0k
Katja Komossa Germany	23	3.0k 0.9×	519 0.5×	756 0.7×	545 0.6×	526 0.8×	26	4.3k
Joseph Peuskens Belgium	37	3.4k 1.0×	638 0.6×	697 0.7×	676 0.7×	361 0.6×	147	4.6k
Robert Goldman United States	36	3.9k 1.2×	1.0k 1.0×	1.2k 1.1×	477 0.5×	1.4k 2.2×	100	5.4k
William H. Carson United States	52	7.0k 2.1×	742 0.7×	1.5k 1.5×	1.9k 2.1×	1.1k 1.8×	141	8.8k
Jean‐Pierre Lindenmayer United States	42	5.2k 1.5×	1.5k 1.4×	1.7k 1.6×	592 0.6×	1.1k 1.8×	134	6.9k

Countries citing papers authored by Robert Lasser

Since Specialization

Citations

This map shows the geographic impact of Robert Lasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lasser more than expected).

Fields of papers citing papers by Robert Lasser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lasser. The network helps show where Robert Lasser may publish in the future.

Co-authorship network of co-authors of Robert Lasser

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Lasser. A scholar is included among the top collaborators of Robert Lasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Lasser. Robert Lasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deligiannidis, Kristina M., Leslie Citrome, Sarah Acaster, et al.. (2023). Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression. The Journal of Clinical Psychiatry. 84(1). 32 indexed citations

Deligiannidis, Kristina M., Samantha Meltzer‐Brody, Robert Lasser, et al.. (2023). Effect of zuranolone on insomnia symptoms in patients with postpartum depression in the SKYLARK study. American Journal of Obstetrics and Gynecology. 228(1). S272–S272. 3 indexed citations

Parikh, Sagar V., Scott T. Aaronson, Sanjay J. Mathew, et al.. (2023). Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 49(2). 467–475. 15 indexed citations

Bonthapally, Vijayveer, Ellison Suthoff, P. Hodgkins, et al.. (2018). PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER. Value in Health. 21. S287–S287. 1 indexed citations

Ostrowitzki, Susanne, Robert Lasser, Ernest Dorflinger, et al.. (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer s Research & Therapy. 9(1). 95–95. 411 indexed citations breakdown →

Findling, Robert L., Ben Adeyi, Bryan Dirks, et al.. (2013). Parent-Reported Executive Function Behaviors and Clinician Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in Children Treated with Lisdexamfetamine Dimesylate. Journal of Child and Adolescent Psychopharmacology. 23(1). 28–35. 7 indexed citations

Trivedi, Madhukar H., Andrew J. Cutler, Cynthia Richards, et al.. (2013). A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram. The Journal of Clinical Psychiatry. 74(8). 802–809. 37 indexed citations

Mattingly, Gregory W., Richard H. Weisler, Joel Young, et al.. (2013). Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 13(1). 39–39. 30 indexed citations

Jain, Rakesh K., et al.. (2011). Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child and Adolescent Psychiatry and Mental Health. 5(1). 35–35. 23 indexed citations

10.

Turgay, Atilla, Lawrence Ginsberg, Elias Sarkis, et al.. (2010). Executive Function Deficits in Children with Attention-Deficit/Hyperactivity Disorder and Improvement with Lisdexamfetamine Dimesylate in an Open-Label Study. Journal of Child and Adolescent Psychopharmacology. 20(6). 503–511. 21 indexed citations

11.

Findling, Robert L., Ben Adeyi, Gary Chen, et al.. (2010). Clinical Response and Symptomatic Remission in Children Treated With Lisdexamfetamine Dimesylate for Attention-Deficit/Hyperactivity Disorder. CNS Spectrums. 15(9). 559–568. 10 indexed citations

12.

Lasser, Robert, Cynthia A. Bossie, Young Zhu, Julie Locklear, & John M. Kane. (2007). Long-Acting Risperidone in Young Adults with Early Schizophrenia or Schizoaffective Illness. Annals of Clinical Psychiatry. 19(2). 65–71. 19 indexed citations

13.

Docherty, John P., et al.. (2007). Evaluation of a Treatment Manual for Risperidone Long-Acting Injectable. Community Mental Health Journal. 43(3). 267–280. 1 indexed citations

14.

Rapaport, Mark Hyman, Georges M. Gharabawi, Carla M. Canuso, et al.. (2006). Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. Neuropsychopharmacology. 31(11). 2505–2513. 104 indexed citations

15.

Simpson, George M., Ramy Mahmoud, Robert Lasser, et al.. (2006). A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder. The Journal of Clinical Psychiatry. 67(8). 1194–1203. 71 indexed citations

16.

Lauriello, John, et al.. (2004). Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Research. 72(2-3). 249–258. 26 indexed citations

17.

Os, Jim van, Cynthia A. Bossie, & Robert Lasser. (2004). Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. International Clinical Psychopharmacology. 19(4). 229–232. 42 indexed citations

18.

Lasser, Robert, Cynthia A. Bossie, Georges M. Gharabawi, Mariëlle Eerdekens, & Henry A. Nasrallah. (2004). Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. Journal of Affective Disorders. 83(2-3). 263–275. 44 indexed citations

19.

Hampel, Harald, Stefan Teipel, Frank Padberg, et al.. (1999). Discriminant power of combined cerebrospinal fluid τ protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18–23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7–12, 1998, Los Angeles, CA, USA.1. Brain Research. 823(1-2). 104–112. 72 indexed citations

20.

Sunderland, Trey, Robert Lasser, Robert Levin, & Ruth Dukoff. (1997). Depression in the elderly. International Clinical Psychopharmacology. 12. S15–S18. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact